Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
ImmunityBio Inc (NASDAQ: IBRX) closed the day trading at $2.59 down -3.00% from the previous closing price of $2.67. In other words, the price has decreased by -$3.00 from its previous closing price. On the day, 8.15 million shares were traded. IBRX stock price reached its highest trading level at $2.67 during the session, while it also had its lowest trading level at $2.57.
On March 06, 2025, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $8. On January 10, 2025, BTIG Research started tracking the stock assigning a Buy rating and target price of $6.BTIG Research initiated its Buy rating on January 10, 2025, with a $6 target price.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IBRX now has a Market Capitalization of 2448209408 and an Enterprise Value of 3138148608. For the stock, the TTM Price-to-Sale (P/S) ratio is 43.25. Its current Enterprise Value per Revenue stands at 55.444 whereas that against EBITDA is -11.663.
Stock Price History:
The Beta on a monthly basis for IBRX is 0.18, which has changed by -0.2724719 over the last 52 weeks, in comparison to a change of 0.16333759 over the same period for the S&P500. Over the past 52 weeks, IBRX has reached a high of $7.48, while it has fallen to a 52-week low of $1.83. The 50-Day Moving Average of the stock is 1.52%, while the 200-Day Moving Average is calculated to be -8.07%.
Shares Statistics:
Over the past 3-months, IBRX traded about 8.90M shares per day on average, while over the past 10 days, IBRX traded about 12548470 shares per day. A total of 915.63M shares are outstanding, with a floating share count of 98.33M. Insiders hold about 89.60% of the company’s shares, while institutions hold 13.20% stake in the company. Shares short for IBRX as of 1756425600 were 75307294 with a Short Ratio of 8.46, compared to 1753920000 on 77068923. Therefore, it implies a Short% of Shares Outstanding of 75307294 and a Short% of Float of 25.869999999999997.
Earnings Estimates
The company has 3.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is -$0.11, with high estimates of -$0.09 and low estimates of -$0.14.
Analysts are recommending an EPS of between -$0.38 and -$0.51 for the fiscal current year, implying an average EPS of -$0.44. EPS for the following year is -$0.28, with 3.0 analysts recommending between -$0.26 and -$0.3.
Revenue Estimates
5 analysts predict $31.88M in revenue for the current quarter. It ranges from a high estimate of $38.11M to a low estimate of $27.5M. As of the current estimate, ImmunityBio Inc’s year-ago sales were $6.11MFor the next quarter, 5 analysts are estimating revenue of $35.29M. There is a high estimate of $47.64M for the next quarter, whereas the lowest estimate is $30M.
A total of 5 analysts have provided revenue estimates for IBRX’s current fiscal year. The highest revenue estimate was $128.7M, while the lowest revenue estimate was $100.44M, resulting in an average revenue estimate of $110.16M. In the same quarter a year ago, actual revenue was $14.74MBased on 5 analysts’ estimates, the company’s revenue will be $221.5M in the next fiscal year. The high estimate is $279.4M and the low estimate is $140.83M.
